FilingReader Intelligence
Yipinhong drug receives clinical trial acceptance
August 4, 2025 at 08:11 AM UTC•By FilingReader AI
Guangzhou Yipinhong Pharmaceutical announced China's National Medical Products Administration accepted the clinical trial application for APH03621 tablets, an innovative drug for endometriosis.
The novel oral, non-peptide GnRH receptor antagonist is classified as a Class 1 new drug.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:300723•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Yipinhong Pharmaceutical publishes news
Free account required • Unsubscribe anytime